Renin inhibition in the treatment of diabetic kidney disease (Q38075571)

28 August 2017

1 reference

title

Renin inhibition in the treatment of diabetic kidney disease (English)

1 reference

28 August 2017

Radko Komers

1 reference

28 August 2017

language of work or name

English

0 references

publication date

1 May 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

124

1 reference

28 August 2017

1 reference

28 August 2017

page(s)

553-566

1 reference

Renin inhibitors: novel agents for renoprotection or a better angiotensin receptor blocker for blood pressure lowering?

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Novel drugs targeting hypertension: renin inhibitors and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Direct renin inhibition with aliskiren in hypertension and target organ damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

State-of-the-Art lecture. Antiproliferative actions of angiotensin-(1-7) in vascular smooth muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Angiotensin-(1-7) in kidney disease: a review of the controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

N-acetyl-seryl-aspartyl-lysyl-proline attenuates renal injury and dysfunction in hypertensive rats with reduced renal mass: council for high blood pressure research

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Angiotensin II activates nuclear transcription factor-kappaB through AT1 and AT2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

The incidence and implications of aldosterone breakthrough

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Antihypertensive therapy with aliskiren

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Aliskiren vs. Angiotensin Receptor Blockers in Hypertension: Meta-Analysis of Randomized Controlled Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Combination of direct renin inhibition with angiotensin type 1 receptor blockade improves aldosterone but does not improve kidney injury in the transgenic Ren2 rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

A reduction of unilateral ureteral obstruction-induced renal fibrosis by a therapy combining valsartan with aliskiren.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Activation of a local renin angiotensin system in podocytes by glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Aliskiren combined with losartan in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Prorenin and (pro)renin receptor: a review of available data from in vitro studies and experimental models in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

(Pro)renin and its receptors: pathophysiological implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

The putative (pro)renin receptor blocker HRP fails to prevent (pro)renin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Associations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Renal (pro)renin receptor contributes to development of diabetic kidney disease through transforming growth factor-β1-connective tissue growth factor signalling cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

(Pro)renin receptor-mediated signal transduction and tissue renin-angiotensin system contribute to diabetes-induced retinal inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Prorenin and its ancient receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Slowly progressive, angiotensin II-independent glomerulosclerosis in human (pro)renin receptor-transgenic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

(Pro)renin receptor peptide inhibitor "handle-region" peptide does not affect hypertensive nephrosclerosis in Goldblatt rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Dose-dependent titration of prorenin and blood pressure in Cyp1a1ren-2 transgenic rats: absence of prorenin-induced glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

The (Pro)renin receptor: site-specific and functional linkage to the vacuolar H+-ATPase in the kidney.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

The (pro)renin receptor/ATP6AP2 is essential for vacuolar H+-ATPase assembly in murine cardiomyocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Requirement of prorenin receptor and vacuolar H+-ATPase-mediated acidification for Wnt signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Prorenin receptor is essential for normal podocyte structure and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Prorenin receptor is essential for podocyte autophagy and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Combining angiotensin II blockade and renin receptor inhibition results in enhanced antifibrotic effect in experimental nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Podocyte COX-2 Exacerbates Diabetic Nephropathy by Increasing Podocyte (Pro)renin Receptor Expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

1,25-Dihydroxyvitamin D3decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

22-Oxacalcitriol prevents progressive glomerulosclerosis without adversely affecting calcium and phosphorus metabolism in subtotally nephrectomized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Antiproteinuric effect of oral paricalcitol in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Plasma 25-hydroxyvitamin D and regulation of the renin-angiotensin system in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Independent association between 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D and the renin-angiotensin system: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Targeted vitamin D receptor expression in juxtaglomerular cells suppresses renin expression independent of parathyroid hormone and calcium

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

1,25-Dihydroxyvitamin D3 suppresses high glucose-induced angiotensinogen expression in kidney cells by blocking the NF-{kappa}B pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Suppression of renin-angiotensin gene expression in the kidney by paricalcitol

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Identification of the vitamin D receptor in various cells of the mouse kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

CRF2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

The cardiovascular physiologic actions of urocortin II: acute effects in murine heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Endogenous urocortins reduce vascular tone and renin-aldosterone/endothelin activity in experimental heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Integrated hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Urocortin 2 infusion in human heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Urocortin 2 combined with angiotensin-converting enzyme inhibition in experimental heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Effect of long-term treatment with urocortin on the activity of somatic angiotensin-converting enzyme in spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Urocortin ameliorates diabetic nephropathy in obese db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Urocortin 1 improves renal function in rats with streptozotocin-induced diabetes by inhibiting overproduction of TGF-beta 1 and VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Urocortin 2 modulates glucose utilization and insulin sensitivity in skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Activation of the succinate receptor GPR91 in macula densa cells causes renin release.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

The succinate receptor GPR91 in neurons has a major role in retinal angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Discovery of a potent and selective small molecule hGPR91 antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Cyclooxygenase-2 modulates afferent arteriolar responses to increases in pressure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Cyclooxygenase-2 mediates increased renal renin content induced by low-sodium diet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Angiotensin II attenuates renal cortical cyclooxygenase-2 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Effects of cyclooxygenase-2 (COX-2) inhibition on plasma and renal renin in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Inhibition of cyclooxygenase-2 attenuates urinary prostanoid excretion without affecting renal renin expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Hypercalcemia stimulates expression of intrarenal phospholipase A2 and prostaglandin H synthase-2 in rats. Role of angiotensin II AT1 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

RISE IN PLASMA CONCENTRATION OF ALDOSTERONE DURING LONG-TERM ANGIOTENSIN II SUPPRESSION

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Prorenin is the endogenous agonist of the (pro)renin receptor. Binding kinetics of renin and prorenin in rat vascular smooth muscle cells overexpressing the human (pro)renin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

Effect of (pro)renin receptor inhibition by a decoy peptide on renal damage in the clipped kidney of Goldblatt rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FCS20120468

21 January 2018

Identifiers

DOI

10.1042/CS20120468

1 reference

28 August 2017

1 reference